Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $164,941 | $157,145 | $148,202 | $158,894 |
| % Growth | 5% | 6% | -6.7% | – |
| Cost of Goods Sold | $77,552 | $77,264 | $74,600 | $94,810 |
| Gross Profit | $87,389 | $79,881 | $73,602 | $64,084 |
| % Margin | 53% | 50.8% | 49.7% | 40.3% |
| R&D Expenses | $20,478 | $13,588 | $14,325 | $16,145 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $58,127 | $50,410 | $54,537 | $55,861 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $566 | $390 |
| Operating Expenses | $78,605 | $63,998 | $68,862 | $72,006 |
| Operating Income | $8,784 | $15,883 | $4,740 | -$7,922 |
| % Margin | 5.3% | 10.1% | 3.2% | -5% |
| Other Income/Exp. Net | $16,444 | $17,461 | $12,915 | $13,362 |
| Pre-Tax Income | $26,228 | $33,344 | $17,655 | $5,440 |
| Tax Expense | $11,150 | $13,136 | $9,108 | -$4,593 |
| Net Income | $15,078 | $20,208 | $8,547 | $10,033 |
| % Margin | 9.1% | 12.9% | 5.8% | 6.3% |
| EPS | 0.4 | 0.54 | 0.23 | 0.27 |
| % Growth | -25.9% | 134.8% | -14.8% | – |
| EPS Diluted | 0.4 | 0.54 | 0.23 | 0.27 |
| Weighted Avg Shares Out | 37,585 | 37,585 | 37,585 | 37,585 |
| Weighted Avg Shares Out Dil | 37,585 | 37,585 | 37,585 | 37,585 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,834 | $15,496 | $13,972 | $10,890 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8,222 | $7,374 | $7,606 | $7,892 |
| EBITDA | $18,062 | $23,119 | $13,969 | $6,170 |
| % Margin | 11% | 14.7% | 9.4% | 3.9% |